Want to see GB:AVCT full AI Analyst Report?
Top Page
Avacta Group plc
(LSE:AVCT)
Select Model
Select Model
Rating:47Neutral
Price Target:
61.00 p
▼(-5.43% Downside)
Action:Reiterated
Date:08/26/26
The score is held down primarily by weak financial performance (persistent losses, cash burn, and a pressured capital structure). The earnings call adds support through credible clinical execution and differentiated platform data, but financing dependence and timeline risks remain significant. Technicals are mixed/neutral and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Differentiated oncology platform
The pre|CISION platform has shown potentially meaningful tumor-delivery advantages in preclinical comparisons, while its FAP focus addresses a target expressed in many solid tumors. If replicated clinically, this differentiation could support adoption, partnering interest, and a broader oncology pipeline.
Negative Factors
Cash runway and financing dependence
The projected runway is limited relative to the time required for clinical development, and it excludes partnering income. Continued cash consumption means Avacta may need additional financing or a partnership to sustain programs beyond early 2027, creating execution and dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated oncology platform
The pre|CISION platform has shown potentially meaningful tumor-delivery advantages in preclinical comparisons, while its FAP focus addresses a target expressed in many solid tumors. If replicated clinically, this differentiation could support adoption, partnering interest, and a broader oncology pipeline.
Read all positive factors
Avacta Group plc (AVCT) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£299.37M
Dividend YieldN/A
Average Volume (3M)1.84M
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees81
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding489,712,860
10 Day Avg. Volume1,593,990
30 Day Avg. Volume1,838,845
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)£75.00K
Avacta Group plc Business Overview & Revenue Model
Company Description
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, wi...
How the Company Makes Money
Avacta generates revenue primarily from its diagnostics activities and, where applicable, from partnering and commercialization-related inflows tied to its therapeutics platforms. In diagnostics, the company makes money by selling diagnostic reage...
Avacta Group plc Earnings Call Summary
Earnings Call Date:May 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 22, 2027
Earnings Call Sentiment Positive
The call presented multiple important positive developments: on-time clinical execution (first-in-human dosing for AVA6103), promising preclinical metrics (up to ~40x tumor Cmax and ~3x tumor selectivity), strengthened IP, focused R&D investment (+31.5% YoY), cost reductions and a successful recent fundraising that extends runway into early Q1 2027. Offsetting these positives are meaningful near-term financing and timeline risks — limited cash runway without partner income, dependence on partnership to launch pivotal studies, tolerability/dose-selection questions at higher AVA6000 doses, and delays/hold status for the Affimer program. On balance the call emphasized substantive scientific and clinical progress alongside manageable but material financing and timing risks.Positive Updates
Clinical Milestone — AVA6103 First Patient Dosed
First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
Negative Updates
Limited Near-Term Cash Runway and Financing Dependency
Cash balance of GBP 16.4m provides runway only into early Q1 2027 assuming no partnering income; company did not disclose monthly burn and remains dependent on further financing or partnerships to fund clinical development beyond that point.
Read all updates
Q4-2025 Updates
Positive
Negative
Clinical Milestone — AVA6103 First Patient Dosed
First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
Read all positive updates
Company Guidance
The call guided a busy 2026 timetable and detailed financial and clinical metrics: R&D spend was GBP 18.8m in FY2025 (up from GBP 14.3m), administrative costs ~GBP 10m (down from GBP 12m), net operating cash outflow GBP 22.64m (vs GBP 24.94m in 2024), and the company has raised GBP 32.5m over the last 18 months (including an oversubscribed GBP 10m placing), leaving cash of GBP 16.4m at end-April 2026 and a runway into early Q1 2027 (assumes no partnering income). Clinically, AVA6103 (FOCUS‑01) dosed its first patient on time in March 2026, is enrolling across ~7–9 U.S. Phase Ia sites for six advanced tumor types (no UK centers), and initial Phase I data are expected by end‑2026 (late Q4); AVA6000 continues in Phase Ia/Ib with a recommended dose for expansion of 310 mg/m2 (other cohorts: 385, 385/200, 250) and Phase Ib/efficacy and cardiac‑safety data to be presented H1 2026 (ASCO/BIO). Pipeline timing also includes AVA6207 payload disclosures targeted in Q3 2026 and candidate selection in H2 2026; preclinical metrics cited include up to 40x higher tumor Cmax for released exatecan versus daruxtecan and ~3x higher tumor selectivity index versus ADCs, and the platform targets FAP expressed in ~90% of solid tumors.Avacta Group plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
27
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 113.00K | 113.00K | 113.00K | 2.85M | 9.65M | 2.94M |
| Gross Profit | -990.00K | 113.00K | 113.00K | 2.84M | 7.24M | -2.50M |
| EBITDA | -30.64M | -28.96M | -17.68M | -14.13M | -34.78M | -26.69M |
| Net Income | -40.38M | -38.38M | -52.84M | -24.95M | -36.94M | -26.32M |
Balance Sheet | ||||||
| Total Assets | 30.94M | 29.42M | 48.27M | 73.19M | 92.65M | 47.00M |
| Cash, Cash Equivalents and Short-Term Investments | 20.27M | 16.86M | 12.87M | 16.63M | 41.78M | 26.19M |
| Total Debt | 19.86M | 14.92M | 22.93M | 23.51M | 62.94M | 1.70M |
| Total Liabilities | 27.17M | 26.94M | 38.99M | 51.39M | 74.21M | 5.78M |
| Stockholders Equity | 3.77M | 2.48M | 9.28M | 21.80M | 18.44M | 41.22M |
Cash Flow | ||||||
| Free Cash Flow | -25.55M | -24.80M | -23.94M | -16.13M | -17.03M | -21.82M |
| Operating Cash Flow | -25.53M | -24.75M | -23.60M | -14.87M | -16.43M | -20.51M |
| Investing Cash Flow | 1.10M | 9.90M | -1.43M | -9.00M | -25.04M | 18.70M |
| Financing Cash Flow | 30.70M | 13.61M | 26.09M | -1.30M | 56.90M | 232.00K |
Avacta Group plc Technical Analysis
Negative
64.50
Price Trends
69.17
Negative
69.41
Negative
68.68
Negative
Market Momentum
-2.13
Positive
33.12
Neutral
12.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AVCT, the sentiment is Negative. The current price of 64.5 is below the 20-day moving average (MA) of 65.78, below the 50-day MA of 69.17, and below the 200-day MA of 68.68, indicating a bearish trend. The MACD of -2.13 indicates Positive momentum. The RSI at 33.12 is Neutral, neither overbought nor oversold. The STOCH value of 12.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AVCT.
Avacta Group plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | £82.07M | -4.57 | -316.73% | ― | -56.10% | -16.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £289.31M | 157.04 | 0.14% | ― | -4.11% | -96.92% | |
47 Neutral | £299.37M | -6.74 | -1293.07% | ― | ― | ― | |
47 Neutral | £37.37M | 165.00 | 3.75% | ― | ― | ― | |
44 Neutral | £107.89M | -5.09 | 128.87% | ― | -100.00% | -30.39% | |
43 Neutral | £2.74M | -2.23 | -83.53% | ― | ― | 93.02% |
* Healthcare Sector Average
GB:AVCT
Avacta Group plc
61.50
-8.50
-12.14%
GB:NFX
Nuformix Plc
0.11
-0.23
-68.18%
GB:PRTC
PureTech Health
118.00
-16.00
-11.94%
GB:SCLP
Scancell Holdings
89.00
-7.50
-7.77%
GB:4BB
4basebio UK Societas
530.00
-255.00
-32.48%
GB:AREC
Arecor Therapeutics PLC
82.50
11.00
15.38%
Avacta Group plc Corporate Events
Business Operations and Strategy
Avacta to Showcase AVA6000 and AVA6103 Data at ESMO 2026
Positive
Oct 14, 2026
Avacta Group plc will highlight new clinical and preclinical data from its pre|CISION® oncology pipeline at the European Society for Medical Oncology 2026 Congress in Madrid later this month. The company is seeking to demonstrate the potentia...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Avacta to Present Interim Results as It Advances Next-Generation Oncology Pipeline
Positive
Oct 12, 2026
Avacta Group plc, through its Avacta Therapeutics division, operates as a clinical-stage life sciences company developing targeted oncology drugs based on its proprietary pre|CISION® platform. The technology uses the tumor-specific protease F...
Business Operations and StrategyPrivate Placements and Financing
Avacta Raises £12.5m to Extend Runway and Advance Oncology Pipeline
Positive
Oct 6, 2026
Avacta has raised £12.5 million through a placing and director-led subscription of new ordinary shares at 68 pence, representing about 3.9% of its existing share capital and a modest discount to the recent market price. The funding extends th...
Business Operations and StrategyPrivate Placements and Financing
Avacta launches £12.5m share placing to fund oncology pipeline and extend cash runway
Positive
Oct 5, 2026
Avacta Group plc, the AIM-listed parent of Avacta Therapeutics, operates in the oncology-focused life sciences sector, advancing a portfolio of pre|CISION®-based drug candidates designed to deliver highly potent cancer therapies directly to t...
Business Operations and StrategyPrivate Placements and Financing
Avacta Enters AIM Capital Access Window for Equity Raise After AVA6103 Milestone
Positive
Sep 30, 2026
Avacta Therapeutics plans to undertake an equity capital raise on AIM and has entered a voluntary Capital Access Window to temporarily pause trading in its shares while the fundraising is arranged. The move follows recent clinical proof of mechani...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Avacta strengthens finances as pre|CISION cancer pipeline gains clinical momentum
Positive
Sep 30, 2026
Avacta reported unaudited interim results for the first half of 2026, highlighting strong clinical and preclinical progress across its pre|CISION oncology pipeline, led by AVA6103 and AVA6000. Early Phase 1 data for AVA6103 show a favorable safety...
Business Operations and Strategy
Avacta’s pre|CISION Platform Wins UK Pharma R&D Award as AVA6103 Advances in Oncology Trials
Positive
Sep 25, 2026
Avacta Group plc has secured the Research and Development Achievement Award at the Pharma Industry Awards UK 2026 for its proprietary pre|CISION® platform. The recognition highlights the company’s rapid progress over the past year in ad...
Business Operations and Strategy
Avacta’s AVA6103 Trial Data Boost Confidence in Next-Gen Pancreatic Cancer Therapy
Positive
Sep 25, 2026
Avacta has presented the design of its FOCUS-01 Phase 1 trial and new preclinical data for AVA6103 at the AACR Conference on Pancreatic Cancer, underscoring the drug’s potential in pancreatic ductal adenocarcinoma. AVA6103, a FAP-enabled pre...
Business Operations and StrategyProduct-Related Announcements
Avacta’s AVA6103 Hits Clinical Proof of Mechanism, Outperforms Enhertu in Preclinical Study
Positive
Sep 16, 2026
Avacta has reported clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate, in the ongoing Phase 1 FOCUS-01 trial in solid tumors. Early Phase 1a data show a clean safety profile acr...
Business Operations and StrategyExecutive/Board Changes
Avacta strengthens board with new audit chair amid oncology push
Positive
Sep 14, 2026
Avacta Therapeutics, part of Avacta Group plc, is a clinical-stage biopharmaceutical and life sciences company focused on oncology. Its proprietary pre|CISION platform uses fibroblast activation protein-based tumor-specific activation to deliver p...
Business Operations and StrategyPrivate Placements and Financing
Avacta Cuts Convertible Bond Balance with Accelerated Cash Repayment
Positive
Sep 4, 2026
Avacta Group plc has received and settled an accelerated payment notice related to its deferred April 2026 quarterly convertible bond repayment, electing to pay the £2.613 million installment in cash. This payment covers £2.4 million of ...
Business Operations and StrategyExecutive/Board Changes
Avacta awards management share options tied to oncology pipeline milestones
Positive
Sep 1, 2026
Avacta has granted new share options to its entire management team under its Equity Share Option Scheme, setting the exercise price at 69 pence, the prevailing market price at grant. Chief executive Christina Coughlin received 13.4 million options...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.